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Background: Pathophysiological processes underlying diabetic-related cardiomyopathies are complex. Mitochondria
dysfunction is often described as a cause of cardiac impairment but its extent may depend on the type of experimental
diabetes. Here we proposed to compare drug- or diet-induced models of diabetes in terms of metabolic features,
cardiac and mitochondrial functions.
Methods: Mice were fed with regular chow or fat-enriched diet. After three weeks, they received either citrate or
streptozotocin injections for five consecutive days. Metabolic parameters, myocardial contractile function and
mitochondrial respiration were measured after three more weeks. Fat mass volumes were assessed by magnetic
resonance imaging. Oral glucose tolerance test, insulin tolerance test, triglyceride and adipocytokine quantification
were evaluated to establish metabolic profiles. Cardiac function was assessed ex vivo onto a Langendorff column.
Isolated cardiac mitochondria respiration was obtained using high-resolution oxygraphy.
Results: Mice fed with the fat-enriched regimen presented abdominal obesity, increased blood glucose, elevated
leptin level, glucose intolerance, and insulin resistance. Mice treated with streptozotocin, independently of the
regimen, lost their capacity to release insulin in response to glucose ingestion. Mice fed with regular chow diet
and injected with streptozotocin developed cardiac dysfunction without mitochondrial respiration defect. However,
both groups of high-fat diet fed mice developed cardiac alterations associated with reduction in mitochondrial oxygen
consumption, despite an increase in mitochondrial biogenesis signalling.
Conclusions: We explored three animal models mimicking type 1 and 2 diabetes. While cardiac dysfunction was
present in the three groups of mice, mitochondrial respiration impairment was only obvious in models reproducing
features of type 2 diabetes.
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affects more than 25 million people in the United States
and will impinge 366 million people in the world in 2030
[1]. Despite established compounds or drugs in develop-
ment [2] and surgical interventions [3], human and eco-
nomical costs remain enormous. Development of new
experimental models reproducing diabetes mellitus and its
complications is indispensable to have a deeper under-
standing of the pathophysiology and to develop innovative
therapeutics.
Several species are used to reproduce diabetes such as
nonhuman primates [4] or pigs [5]. The most frequently* Correspondence: steve.lancel@univ-lille2.fr
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unless otherwise stated.used animals are rodents, especially mice, because of their
cost, size and availability. On the first hand, spontaneous
monogenic modified mice such as db/db and ob/ob mice
[6,7] as well as animals fed with high-fat diet have been
developed. They share common features of type 2 dia-
betes, such as glucose intolerance, insulin resistance and
dyslipidemia. On the other hand, OVE26 and Akita mice
or injection of the toxic pancreatic agent streptozotocin
(STZ) have been documented to reproduce characteristics
of type 1 diabetes [8-10]. In both cases, cardiovascular
dysfunction has been described either in basal condi-
tions or under biological stress like β-adrenergic stimu-
lation [11].
Among the numerous hypotheses advanced to ex-
plain diabetes-related cardiomyopathy, including calciumral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Nutrient composition and energy sources of
normal and high-fat diets
Normal diet High-fat diet
Crude protein (%) 16.4 24.1
Fat (%) 4 34.6
Carbohydrate (%) 48.5 25.3
Fiber (%) 18.5 6
Ash (%) 4.9 6
Energy density (kJ/g) 12.6 24
Calories from proteins (%) 22 19
Calories from fat (%) 12 60
Calories from carbohydrates (%) 66 21
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[12], mitochondrial dysfunction has been described as one
of the most important. Indeed, mitochondria occupy ap-
proximately 30% of the heart volume [13] and these or-
ganelles are constantly solicited to produce ATP, which is
required for cardiac contraction. It is thus obvious that de-
fects in mitochondrial population quality may impair car-
diac function. Many murine models of type 2 diabetes,
including mice with genetic modifications, fed with high-fat
diet associated or not with low doses of STZ, extensively
described an association between cardiac dysfunction and
mitochondria alterations, including reduced ATP pro-
duction, defects in mitochondrial respiration despite
stimulation of biogenesis signalling and modified prote-
ome [14-16]. Such observations have also been obtained
in the human heart from type 2 diabetic patients [17].
Surprisingly, cardiac mitochondrial dysfunction in models
of type 1 diabetes is less characterized, differs from type 2
diabetes and from a model to another [10,18,19]. Finally,
because of the variety of protocols published in distinct pa-
pers, it is not clear whether the intensity of mitochondrial
dysfunction is correlated with the severity of cardiac dys-
function and whether mitochondrial impairment occurs at
the same time in both types of diabetes.
In this study, we evaluated cardiac function and respir-
ation of heart mitochondria in three different models of
diabetes. First, we compared metabolic parameters such
as glucose tolerance or insulin resistance in mice fed with
regular chow diet and injected with STZ, mice fed with
high-fat diet treated with citrate buffer or STZ to mice fed
with normal diet injected with citrate buffer. Then, we
measured myocardial contractile function and mitochon-
drial respiration in order to determine whether mitochon-
drial alterations precede diabetic-related cardiomyopathy.
Methods
Experimental models
Five-week old female C57/BL6J mice (Charles River,
L’Arbresle, France) were randomly separated in two
groups: the first one had free access to normal chow diet
(ND), the other one to high-fat diet (HFD, D12492,
SSNIFF, Soest, Germany). Food composition and energy
sources are provided Table 1. Then, both groups of mice
received either streptozotocin (60 mg/kg intraperitone-
ally, 1 injection per day for five consecutive days, Sigma
Aldrich, St Quentin Fallavier, France), or the equivalent
volume of citrate buffer that was used to dissolve strep-
tozotocin (0.1 M, pH 4.5, 1 injection per day for five
days). After injections, mice were housed for three more
weeks and fed ad libitum with their respective food.
Thus, after six weeks of feeding, four groups were ob-
tained: ND/CITRATE, ND/STZ, HFD/CITRATE and
HFD/STZ. There were at least two full days between
tests to avoid potential stress confounding effects. Allexperimental procedures were approved by our institu-
tional guidelines (DDSV Permit Number 59–350206) and
were conducted according to NIH instructions.
Magnetic resonance imaging of fat distribution
Once anesthetized by inhaling isoflurane, mice were im-
aged on a Biospec 7-Tesla magnetic resonance imaging
unit (Biospec, BrukerBioSpin SA, Wissembourg, France).
Sequences were acquired in the abdomen, around the
kidney region. The T1 spin-echo images were obtained
with a thickness of 1 mm, a repetition time of 200 ms
and an echo time of 27 ms. Data were analyzed with
OsiriX software. Subcutaneous and abdominal fat mass
volumes (expressed in cm3) were determined manually.
Oral glucose tolerance test OGTT
In order to evaluate glucose tolerance, mice were sub-
jected to a 12-h fasting period. Then, they were force-
fed with a glucose solution (2 mg/g total body weight) in
approximately 200 μL of water. One drop of blood ob-
tained from a tail incision was used to determine glucose
concentration by the use of a glucose meter. Measure-
ments were obtained before ingestion and 10, 20, 30, 60
and 120 min after glucose challenge.
Insulin tolerance test ITT
Fasted mice received intraperitoneally fast insulin (0.5 mU/g
total body weight in saline solution). Blood glucose concen-
tration was measured before and 15, 30 and 60 min after
the injection.
Blood collection and analysis of plasma
After fasting, tail incision was made and blood (100 μL)
was collected into EDTA-coated tubes. Sample was spun
at 1,000 g for 15 min and plasma was aliquoted and
stored at −80°C until use. Plasmatic adiponectin, leptin,
TNF-α, IL-6 and MCP1 were quantified with multiplex
immunoassay kits (Millipore, Molsheim, France). True
triglycerides were measured with the determination kit
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ing to manufacturer’s instructions.
Insulin response to glucose challenge
Blood samples (30 μL) were collected from fasted mice.
Then, animals were force-fed with a glucose solution
(2 mg/g total body weight). Ten minutes later, 30 μL of
blood were withdrawn for plasma preparation. Then, in-
sulin was measured with the insulin (Mouse) EIA kit
(Alpco, Salem, NH, USA) according to manufacturer’s
instructions.
Pancreas immunohistochemistry
After mouse euthanasia, pancreas was dissected, fixed in
Bouin solution and embedded in paraffin. Then, sections
of 6 μm thickness were prepared and put onto superfrost
slides. After paraffin removal, tissue was rehydrated in
solutions of decreasing alcohol concentration. Slides were
immersed into citrate buffer (0.01 M, pH 6) in order to
unmask antigens. Then, endogenous peroxidase activity
was blocked by incubating sections in 3% H2O2 diluted in
methanol. After incubation in PBS + 3% bovine serum al-
bumin, monoclonal anti-insulin antibody (1/100, AbD
Serotec Colmar, France) was added to the sections and
incubated at 4°C overnight. After rinsing, peroxidase-
conjugated anti-mouse antibody was incubated for 1 h
at room temperature. 3,3′-diaminobenzidine (Bethyl
Laboratories, Inc., Montgomery, TX, USA) was applied
for 15 min at room temperature. Slides were counter-
stained by immersion in hematoxylin. After rinsing,
slides were mounted and observed under microscope
with × 100 and × 400 magnification.
Isolated and perfused heart
After cervical dislocation, heart was excised and aorta was
cannulated onto a Langendorff column. Heart was per-
fused in a retrograde manner with oxygenated (O2 95%,
CO2 5%) modified Krebs-Henseleit (consisting in NaCl
120 mM, KCl 4.8 mM, KH2PO4 1.2 mM, MgSO4 1.2 mM,
NaHCO3 25 mM, CaCl2 1.25 mM, glucose 11 mM) at 37°C
with a constant perfusion rate (2.5 mL/min). In some ex-
periments, 0.8 μg/mL isoprenaline was added in the buf-
fer. A metal hook was inserted into the apex. The hook
was connected to a calibrated dynamometer, which was
connected to a pre-amplifier linked to the acquisition sta-
tion (Powerlab, ADInstrument, Oxford, United Kingdom).
Heart spontaneously beat with a 2 g preload. Developed
force and its first derivatives were measured in absence or
presence of isoprenaline. Heart work was defined as the
product of force x heart frequency.
Mitochondria isolation and function
Cardiac mitochondria were isolated as previously described
[20]. Mitochondria (200 μg) were introduced into O2Koxygraph chambers (Oroboros Instruments, Innsbruck,
Austria) to evaluate their oxygen consumption in presence
of different compounds. In a first series of experiments,
pyruvate (5 mM), glutamate (5 mM) and malate (2 mM)
were added. After signal stabilization, ADP (0.5 mM) was
injected in order to measure oxygen consumption when
oxidative phosphorylation occurs. The second series of ex-
periments consisted in adding palmitoylcarnitine (20 μM)
in presence of malate (2 mM). Then ADP (0.5 mM) was
injected into the chambers in order to evaluate respiration
with substrates subjected to β-oxidation.
Mitochondrial DNA copy number
Total DNAs were extracted with QIAamp DNA mini kit
(Qiagen, Courtaboeuf, France) according to manufac-
turer’s instructions. Nucleic acid concentration and purity
were measured at 260 and 280 nm with the Nanodrop
reader (Nanodrop products, Wilmington, DE, USA). Then
40 ng of DNA were used to perform quantitative PCR
with FastStart Universal SYBR Green (Roche Applied
Science, Meylan, France). The following primers were
utilized: mtCOII Forward AACCATAGGGCACCAAT
GATAC, Reverse GGATGGCATCAGTTTTAAGTCC




Total RNAs were extracted from 20 mg heart tissue with
1 mL Trizol reagent and purified with PureLink Micro-
to-Midi kit (Life Technologies SAS, Saint Aubin, France).
DNA was systematically removed by DNase treatment.
Then, reverse transcription with random hexamers and
Transcriptor First Strand cDNA Synthesis kit (Roche Ap-
plied Science) was performed according to manufacturer’s
instructions. Amplification was done with FastStart Uni-
versal SYBR Green and the following primers: PGC-1α
Forward CGGAAATCATATCCAACCAG, Reverse TGAG




Presented data are means ± SEM. Analysis was per-
formed with GraphPad Prism software 5.0 (San Diego,
CA, USA). Statistical analysis was carried out using two-
tailed unpaired t-test when comparing two groups and
one-way ANOVA followed by Bonferroni post-hoc tests
when comparing more than three groups. Two-way
ANOVA was performed to determine time influence on
the measured parameters and was used for analysis of
food intake, calorie intake, variation of weight, OGTT
and ITT.
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Food intake, weight gain and fat distribution
Prior to cardiovascular and mitochondrial evaluations,
we compared metabolic phenotypes of ND/STZ, HFD/
CITRATE and HFD/STZ to ND/CITRATE. Three weeks
after the beginning of the regimen, mice fed with HFD
started eating less than their littermates under ND
(Figure 1A). Despite this difference, cumulative energyFigure 1 Food intake, weight gain and fat volume in the four groups
over weeks of feeding. (C) Gain of weight compared to initial weight. Circl
STZ mice. Arrows indicate when streptozotocin (STZ) or citrate buffer were
HFD/CITRATE, HFD/STZ mice fed for 6 weeks. Arrows indicate subcutaneou
(F) abdominal fat. n = 8 per group, *p < 0.05 vs. ND/CITRATE mice.intake in the HFD mice was significantly higher than in
the ND animals from the first to the last week of spe-
cific diet (Figure 1B). Mouse weight increased faster in
HFD groups than in the ND ones (Figure 1C). Injections
of STZ (60 mg/kg total body weight) did not modify the
amount of ingested food as ND/STZ and HFD/STZ ate as
much as ND/CITRATE and HFD/CITRATE, respectively
(Figures 1A and B). Similarly, body weights betweenof mice. (A) Cumulative food intake and (B) cumulative calorie intake
e: ND/CITRATE, square: ND/STZ, triangle: HFD/CITRATE, diamond: HFD/
injected. (D) MRI images of abdominal region in ND/CITRATE, ND/STZ,
s and abdominal fat. Volume quantification of (E) subcutaneous and
Figure 2 Oral glucose tolerance tests of mice fed for one, three
and six weeks. After glucose ingestion, blood glucose
concentration was measured at 0, 10, 20, 30, 60, 120 min later in
mice fed for one (A), three (B) or six (C) weeks. Circle: ND/CITRATE,
square: ND/STZ, triangle: HFD/CITRATE, diamond: HFD/STZ mice.
n = 16 per group, *p < 0.05 vs. ND/CITRATE.
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groups were not significantly different (Figure 1C).
To further characterize their phenotypes, mice were
subjected to MRI to quantify fat mass. As depicted in
Figure 1D, fat distribution between citrate- and STZ-
injected ND mice was similar. These results were con-
firmed by image quantification (Figures 1E and F). In
both groups of HFD mice, hypersignal was stronger in
subcutaneous and abdominal compartments (Figure 1D).
Analysis revealed that, compared to ND/CITRATE, sub-
cutaneous fat volume increased by 77% while abdominal
fat volume doubled (Figures 1E and F) in both HFD
groups. STZ injections had no effects on fat deposition
neither in ND nor in HFD mice (Figures 1D-F).
Glucose intolerance
OGTT was performed to evaluate glucose tolerance in
the four different groups either after one week of feeding
(no injections), three weeks (just before injections of cit-
rate or STZ), or six weeks, i.e. three weeks after the first
injections. As presented Figure 2A, mice had similar re-
sponse to glucose ingestion after one week of HFD with
no injections. After three weeks of feeding (Figure 2B),
there were no significant differences between ND mice
that will subsequently be injected with citrate buffer
(ND/CITRATE) or STZ (ND/STZ). Similar results were
obtained within the HFD groups (Figure 2B). Neverthe-
less, as soon as three weeks under specific regimens,
both groups of mice fed with HFD started showing glu-
cose intolerance, as their blood glucose concentration
remained elevated 60 min after ingestion compared to
ND (Figure 2B). Finally, OGTT was performed three
weeks after citrate or STZ injections (Figure 2C). Com-
pared to ND/CITRATE mice, ND/STZ and mice fed
with HFD that received or not STZ had higher glucose
concentration 20, 30 and 60 min after glucose force-
feeding. Plus, after two hours, glucose concentration
remained above 200 mg/dL in the HFD/STZ group
(Figure 2C). All subsequent experiments were performed
six weeks after the onset of the regimen.
Insulin resistance and secretion capacity
In HFD and HFD/STZ groups, slope of glucose con-
centration reduction after insulin injection was re-
duced compared to ND/CITRATE mice (Figure 3A). In
addition, after 60 min, blood glucose concentration was
reduced by only 20% in HFD-STZ and HFD/CITRATE
while it decreased by 50% in both ND/CITRATE and
ND/STZ (Figure 3A). ND/STZ mice had significant
higher glucose concentrations 15 and 30 min after insu-
lin injection.
We then evaluated glucose-stimulated insulin release
by measuring circulating insulin before and after an oral
glucose challenge. As illustrated in Figure 3B, insulin levelsunderwent a 11-fold increase either in ND/CITRATE or
HFD/CITRATE mice. Mice treated with STZ lost their
capacity to respond to glucose as insulin levels barely in-
creased by 3 (Figure 3B). Moreover HFD/CITRATE mice
significantly released more insulin than ND/CITRATE lit-
termates (Figure 3B).
Finally, we qualitatively evaluated whether such alter-
ations could be attributed to reduced size of pancreatic
Figure 3 Streptozotocin and high-fat diet induced insulin abnormalities after six weeks of feeding. (A) Insulin tolerance test. Blood
glucose was measured 15, 30 and 60 min after insulin injection. n = 10, * p < 0.05 vs. ND/CITRATE. (B) Insulin secretion in response of glucose
ingestion. n = 5, *p < 0.05 compared to fasted conditions, † p < 0.05 HFD/CITRATE vs. ND/CITRATE. (C) Immunohistochemistry of pancreas using
an anti-insulin antibody. Arrows indicate cells with lower staining intensity. Magnifications were ×100 and ×400, as indicated.
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poison targeting β-cells. Islet staining intensity seemed
reduced in ND/STZ and HFD/STZ compared to ND/
CITRATE mice (Figure 3C). In HFD/CITRATE group,
islet size appeared bigger than in ND/CITRATE group
but the staining intensity was not affected (Figure 3C).
As expected, size of islets was reduced in both groups
treated with STZ (Figure 3C).
Metabolic parameters
Blood glucose concentration in fasted animals was
significantly higher, although moderate, in ND/STZ,HFD/CITRATE and HFD/STZ as compared to ND/
CITRATE (Table 2). Triglyceride and leptin levels mildly
augmented in mice fed with HFD, independently of STZ
treatment (Table 2). Inversely, compared to ND/CITRATE,
adiponectin level was divided by 2 in HFD/CITRATE group
while it diminished by 30% in HFD/STZ animals (Table 2).
ND/STZ mice had equivalent amount of adiponectin com-
pared to ND/CITRATE mice (Table 2). Regarding the pro-
inflammatory status, neither MCP-1 (not detectable), nor
TNF-α, nor IL-6 was significantly increased although a
trend could be observed in ND/STZ, HFD/CITRATE and
HFD/STZ compared to ND/CITRATE animals (Table 2).
Figure 4 Cardiac function alterations in diabetic mice. (A)
Spontaneous heart work measured ex vivo and (B) force first
derivatives +/− dF/dt in presence or in absence of isoprenaline.
Circle: ND/CITRATE, square: ND/STZ, triangle: HFD/CITRATE, diamond:
HFD/STZ, n = 4–5 per group, *p < 0.05 vs. ND/CITRATE.
Table 2 Blood parameters after six weeks of diet
ND/CITRATE ND/STZ HFD/CITRATE HFD/STZ
Glucose (mg/dL) 74 ± 2 84 ± 3 * 83 ± 2 * 112 ± 6 *
True triglycerides
(mg/dL)
52 ± 4 60 ± 10 90 ± 8 * 103 ± 11 *
Leptin (ng/mL) 1.0 ± 0.2 1.1 ± 0.1 1.9 ± 0.2 * 2.3 ± 0.3 *
Adiponectin
(μg/mL)
30.3 ± 3.1 30.3 ± 6.1 15.6 ± 0.9 * 21.4 ± 1.5 *
TNF-α (pg/mL) 3.8 ± 0.5 6.0 ± 1.2 5.4 ± 0.8 4.5 ± 0.4
IL-6 (pg/mL) 7.5 ± 0.9 12.4 ± 2.0 14.7 ± 1.8 13.0 ± 2.8
Data are means ± SEM. n = 8–10 per group, *p < 0.05.
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Isolated heart function was assessed onto a Langendorff
apparatus. Under basal conditions, heart work (Figure 4A)
and first derivatives + dF/dt and -dF/dt (Figure 4B), index
of contractility and relaxation respectively, were reduced
in ND/STZ, HFD/CITRATE and HFD/STZ compared to
ND/CITRATE. In presence of isoprenaline, a β-adrenergic
receptor agonist, both ND/CITRATE and HFD/CITRATE
hearts increased cardiac work (Figure 4A) and first deriva-
tives (Figure 4B). In contrast, ND/STZ and HFD/STZ
hearts did not significantly respond to β-adrenergic stimu-
lation (Figure 4).
Mitochondrial respiration and biogenesis
Mitochondria were isolated from heart and analyzed
with an oxygraph. When mitochondria were incubated
in presence of palmitoylcarnitine and malate, respiration
rate was similar in the four groups. Addition of ADP in
the respiration media led to a 6.8- and 6.1-fold increase
in oxygen consumption in the ND/CITRATE and ND/
STZ mice, respectively (Figure 5A). This increase in res-
piration was significantly lower in HFD/CITRATE and
HFD/STZ mice (Figure 5A). Similarly, no differences be-
tween groups were observed in presence of glutamate/
malate alone (Figure 5B). Activation of oxidative phos-
phorylation by ADP resulted in a 5-fold increase in ND/
CITRATE and ND/STZ whereas it increased by 3 in the
HFD/CITRATE and HFD/STZ (Figure 5B). These mito-
chondrial alterations observed in HFD/CITRATE and
HFD/STZ were associated with an increase in mitochon-
drial biogenesis signalling. Indeed, compared to ND/
CITRATE, mtDNA copy number was higher in HFD/
CITRATE and HFD/STZ (Figure 5C). Similar results
were obtained for PGC-1α mRNA expression (Figure 5D).
Discussion
The aim of this study was to characterize the metabolic
phenotype of three diabetes-related animal models in-
duced by HFD and the pancreatic poison STZ and to
evaluate whether cardiac dysfunction was always associ-
ated with mitochondrial respiration impairment.As a prerequisite before assessment of myocardial and
mitochondrial functions, we evaluated metabolic features
of the three diabetes-related models obtained in C57BL6/J
mice, a strain known to respond to diet-induced obesity
and to develop insulin resistance and glucose intolerance
[21]. First, HFD mice gained more weight and conse-
quently developed both subcutaneous and abdominal adi-
pose tissues, as assessed by MRI. This was associated with
a mild plasma true triglyceride elevation. Visceral adipose
tissue, now considered as an endocrine tissue [22], pro-
duces pro-inflammatory cytokines such as TNF-α and IL-
6 [23]. Here, we could not detect significant elevation in
these two molecules. This may be attributed to the rela-
tively short-term regimen (6 weeks) or to the C57BL6/J
genetic background. Indeed Balb/c or FVB/N mice are
Figure 5 Mitochondrial parameters after six weeks of diet. Isolated mitochondria respiration in presence of (A) palmitoylcarnitine/malate or
(B) glutamate/malate/pyruvate in absence (left) and in presence (middle) of ADP. Respiration ratio refers to right Y axis. (C) Mitochondrial DNA
relatively to genomic DNA. (D) Expression of Pgc-1α mRNA in the four different groups after six weeks. n = 5, *p < 0.05 vs. ND/CITRATE.
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Abdominal adipocytes also secrete leptin and adiponectin.
As expected, the elevation in visceral fat was associated
with increase in leptin circulating levels while adiponectin
was reduced. Despite higher leptin concentration in the
HFD fed animals, food intake barely reduced and mice
kept accumulating fat, consistently with other studies [24].
STZ had no effects on leptin and adiponectin levels.
A deeper analysis of diabetes-related features consisted
in studying glucose intolerance and insulin resistance.
HFD/CITRATE or HFD/STZ mice had a lower rate of
glucose disposal after insulin injection and glucose in-
gestion, as well as a moderate increase in fasting blood
glucose concentration, featuring an insulin resistant status.
Several mediators such as leptin, which reduces insulin-
induced fatty acid oxidation and triacylglycerol synthesis
[25,26], or fatty acids, which compete with glucose for
their mitochondrial oxidation [27,28], are commonly sug-
gested as contributors of insulin resistance and glucose in-
tolerance. As observed in other experimental studies and
in humans [29-31], we also detected bigger pancreatic β-
cell islets and higher plasmatic insulin levels ten minutes
after glucose ingestion in HFD/CITRATE mice. This
metabolic phenotype indicates that HFD/CITRATE micemanifested features of a pre-diabetic state. We reproduced
effects of STZ, an alkylating compound causing beta pan-
creatic cell death, described by others [32-34]. Indeed,
ND/STZ and HFD/STZ mice released less insulin con-
secutively to glucose stimulation. Taken together, these
results suggest that ND/STZ, HFD/CITRATE and HFD/
STZ were more related to type 1 diabetes, pre-diabetes
and established type 2 diabetes, respectively.
Diabetes-related cardiovascular alterations have been
documented in both type 1 and type 2 rodent models
[16,35-38]. Here we aimed to determine whether intrinsic
myocardial contractile function was affected in these dif-
ferent settings of diabetes. In order to avoid confounding
effects of circulating leptin, triglycerides, cytokines or in-
sulin on the heart, we used isolated and perfused heart
preparations onto a Langendorff apparatus. First, isolated
hearts from STZ-treated animals did not respond to β-
adrenergic stimulation. This could be related to a reduc-
tion in β1 and β2 adrenoreceptor expression while the β3
isoform, mediating negative inotropic effect, may rise [39].
Then, despite the mild elevation in fasting blood glucose
and triglyceride concentration and an exploration close to
the onset of diabetes, we found a marked intrinsic con-
tractile dysfunction of the myocardium in the three
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the expense of glucose utilization, expansion of connective
tissue, oxidative stress, calcium mishandling and reduction
in SERCA expression have been proposed to explain dia-
betic cardiac dysfunction [12,35]. In addition, several stud-
ies identified mitochondria as a potential cause of
myocardial dysfunction in diabetes. Thanks to the early
development of diabetic cardiomyopathy, we decided to
explore whether this organ dysfunction was always associ-
ated with mitochondrial impairment.
We highlighted a profound mitochondrial respiration
reduction in insulin-resistant HFD/CITRATE and HFD/
STZ mice. Consistently studies on cardiac-specific knock-
out mice for the insulin receptor (CIRKO) demonstrated
that lack of insulin signalling in the myocardium leads to
impaired contractile function along with mitochondria re-
spiratory defects and ATP synthesis rate reduction that
progress with age [40]. In addition, reduction of mito-
chondrial respiration was associated with stimulation of
mitochondrial biogenesis signalling as evidenced by in-
creased PGC-1α mRNA expression and mtDNA copy
number. PGC-1α is a major transcription factor control-
ling mitochondrial biogenesis. Genetic deletion of PGC-
1α causes reduced cardiac ATP production and the
incapacity to respond to a stress such as exercise or
adrenergic stimulation [41,42]. On the contrary, Lehman
et al. [43] showed that, despite PGC-1α-mediated mito-
chondria number increase, contractile function was se-
verely affected because of sarcomere misalignment. These
studies emphasize that mitochondrial function had to be
tightly regulated to exert beneficial effects on cardiac func-
tion. Mitochondrial population quality also depends on
autophagy and dynamics, processes that are also involved
in diabetes. For instance, in a severe model of type 1 dia-
betes, Xu et al. [44] described that autophagy is reduced
in the diabetic heart. Surprisingly, inhibition of autophagy
exerted cardioprotective effects, probably through at least
in part mitophagy activation. Alterations of mitochondrial
dynamics have also been reported in failing diabetic hu-
man hearts [45]. Although we did not examined oxidative
damage in these hearts, increased in mitochondrial react-
ive oxygen species production may also contribute to the
mitochondrial phenotype. Nakamura et al. [46] demon-
strated that, for instance, in db/db mice, mitochondrial-
derived ROS generation due to hyperglycemia and lipid
accumulation activated p53 and its target SCO2. As a con-
sequence, higher expression of SCO2 resulted in increases
in fatty acid uptake, mitochondrial oxygen consumption
and ROS production.
In the present study, we did not observe defects in
mitochondrial respiration in ND/STZ mice, neither with
pyruvate/glutamate nor with palmitoylcarnitine as sub-
strates, while cardiac dysfunction was patent, suggesting
that defects in mitochondrial respiration per se may notbe the primary cause of cardiac dysfunction. While studies
described similar results in rats [47], others reported that
palmitoylcarnitine-dependent mitochondrial respiration
could remain identical between control and STZ-injected
despite a reduction in ATP production rate [48]. More re-
cently, in a chronic model of type 1 diabetes, Vadvalkar
et al. [49] demonstrated that heart mitochondria may have
substrate inflexibility as their respiration was reduced only
with non-fatty acid substrates. They also showed that pro-
tein lysine acetylation reproduced inhibition of non-fatty
acid oxidation by mitochondria. The authors thus hypoth-
esized that discrete mitochondrial changes such as protein
lysine acetylation could impact oxidative phosphorylation
before the onset of type 1 diabetic cardiomyopathy. How-
ever, in our study, we could not detect mitochondrial im-
pairment with pyruvate/glutamate. This may be explained
by the early investigation after type1-like diabetes induc-
tion as well as the mild phenotype we observed in terms
of hyperglycemia and dyslipidemia. This model may not
recapitulate the whole pathogenesis of a more severe and
chronic type 1 diabetes. Finally, other mitochondrial func-
tions may be affected during diabetes. Indeed a recent re-
port [50] identified that ATP-dependent potassium channel
expression is diminished by type 1 diabetes. As a conse-
quence, diazoxide-induced depolarization was lower in dia-
betic mitochondria. Interestingly, interfibrillar mitochondria
were more sensitive to diazoxide than subsarcolemmal
mitochondria. This result underlines that mitochondrial
populations may be differently affected by diabetes.
In conclusion, mechanisms responsible for the diabetic-
related cardiomyopathies depend on duration, type and
severity of diabetes. Injections of streptozotocin in mice
fed with regular chow diet led to a type-1 like diabetic
mouse model that displayed cardiovascular alterations
without mitochondrial respiration impairment. On the
contrary, cardiac dysfunction of mice fed with HFD that
received or not STZ was associated with a dramatic reduc-
tion in mitochondrial respiration despite mitochondrial
biogenesis activation.
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